Skip to content

AARD AARD Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
$65.65K+260%

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Reported directly by AARD in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's payments of stock issuance costs?
AARD (AARD) reported payments of stock issuance costs of $0 in Q1 2026.
How has AARD's payments of stock issuance costs changed year-over-year?
AARD's payments of stock issuance costs decreased by 100.0% year-over-year, from $2.31M to $0.
What does payments of stock issuance costs mean?
Represents the direct costs incurred in connection with the issuance of equity, such as underwriting fees, legal expenses, and registration costs. Monitoring these costs provides insight into the efficiency of the company's capital raising activities.